Nutra Pharma Corp.
NPHC · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 20.8% | 307.1% | -14.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 62.4% | 32.7% | 35.1% | -150.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | -$0 |
| % Margin | 691.5% | -353.3% | 23,625.7% | -1,909.5% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 528.6% | -935.5% | 22,585.2% | 8,346.6% |
| EPS | 0 | -0 | 0.001 | 0 |
| % Growth | 187.9% | -117.3% | 69.1% | – |
| EPS Diluted | 0 | -0 | 0 | 0 |
| Weighted Avg Shares Out | 8 | 7 | 7 | 7 |
| Weighted Avg Shares Out Dil | 16 | 7 | 14 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | $0 |
| % Margin | 731.1% | -487.1% | 23,565.2% | 8,947.7% |